The incidence of recurrent leukemia more than 10 years after allogeneic bone marrow transplant (alloBMT) is very low. The pathogenesis of late relapse after alloBMT remains unknown. Cytogenetic ...
At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with blast-phase chronic myeloid leukemia (CML) using data from a multi-institution ...
Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma The following represents disclosure information provided by the authors of ...
Routine assessment before cataract surgery in February 2006 showed thrombocytopenia and leukocytosis with circulating blasts. BM biopsy was consistent with recurrent lymphoblastic leukemia (>80% ...
Tertiary lymphoid structures are formations that occur outside of the lymphatic system. They contain immune cells and are similar in structure and function to lymph nodes and other lymphoid structures ...
Chronic myeloid leukemia is a slow-growing type of leukemia. It rarely transforms into more aggressive forms such as acute myeloid or acute lymphoid leukemia. CML can transform into a CML blast crisis ...
A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update. Escalated dosing schedules of CC-486 for ...
The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement. The Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results